Securing R&D Funding Through Partnerships, Grants and Investor Fundraising

「An increase of ¥25.000 million in long-term deposits received, consisting of subsidies awarded through AMED’s Drug Discovery Support Promotion Project and Pre-designation Practical Application Support Project for Orphan Drugs」

「Liabilities at the end of the fiscal year were ¥405.771 million, up ¥19.34 million from the end of the previous fiscal year. The main factor was a ¥78.765 million increase in long-term deposits received representing grants awarded following selection for AMED's Drug Discovery Support Promotion Program / Pre-designation Practical Application Support Program for Orphan Drugs.」

「Liabilities at the end of the interim accounting period were ¥408.864 million, up ¥22.432 million from the end of the previous fiscal year. The main factor was a ¥50 million increase in long-term deposits received representing grants awarded following selection for AMED's Drug Discovery Support Promotion Program / Pre-designation Practical Application Support Program for Orphan Drugs, offset by decreases of ¥9.365 million in accounts payable, ¥10.582 million in accrued expenses and ¥13.797 million in income taxes payable.」

「Liabilities at the end of the fiscal year were ¥386.431 million, up ¥90.965 million from the end of the previous fiscal year. The main factor was a ¥95.077 million increase in long-term deposits received representing grants awarded following selection for AMED's Drug Discovery Support Promotion Program / Pre-designation Practical Application Support Program for Orphan Drugs.」

「The main factors were increases of ¥50 million in long-term deposits received representing grants awarded following selection for AMED's Drug Discovery Support Promotion Program / Pre-designation Practical Application Support Program for Orphan Drugs and ¥21.121 million in accounts payable, offset by a ¥20.318 million decrease in accrued expenses.」

「Liabilities at the end of the fiscal year were ¥295.465 million, up ¥125.36 million from the end of the previous fiscal year. The main factors were increases of ¥28.852 million in accrued expenses and ¥107.5 million in long-term deposits received representing grants awarded following selection for AMED's Drug Discovery Support Promotion Program / Pre-designation Practical Application Support Program for Orphan Drugs, offset by a ¥12.8 million decrease in asset retirement obligations.」

「Liabilities at the end of the third quarter accounting period were ¥241.103 million, up ¥70.998 million from the end of the previous fiscal year. The main factors were increases of ¥82.5 million in long-term deposits received representing grants awarded following selection for AMED's Drug Discovery Support Promotion Program / Pre-designation Practical Application Support Program for Orphan Drugs and ¥29.72 million in accrued expenses, offset by decreases of ¥31.963 million in accounts payable and ¥12.8 million in asset retirement obligations.」

「The main factors were increases of ¥50 million in long-term deposits received representing grants awarded following selection for AMED's Drug Discovery Support Promotion Program / Pre-designation Practical Application Support Program for Orphan Drugs and ¥13.565 million in accrued expenses, offset by decreases of ¥22.06 million in accounts payable and ¥12.8 million in asset retirement obligations.」

「Liabilities at the end of the first quarter accounting period were ¥167.656 million, down ¥2.448 million from the end of the previous fiscal year. The main factors were a ¥25 million increase in long-term deposits received representing grants awarded following selection for AMED's Drug Discovery Support Promotion Program / Pre-designation Practical Application Support Program for Orphan Drugs, offset by decreases of ¥20.237 million in accounts payable, accrued expenses and income taxes payable, and ¥12.8 million in asset retirement obligations.」

「The company recognized, from the current fiscal year, ¥58.987 million in long-term deposits received representing grants awarded following selection for AMED's Drug Discovery Support Promotion Program / Pre-designation Practical Application Support Program for Orphan Drugs.」

「The main factors were the recognition, from the current fiscal year, of ¥46.487 million in long-term deposits received representing grants awarded following selection for AMED's Drug Discovery Support Promotion Program / Pre-designation Practical Application Support Program for Orphan Drugs, ¥7.353 million in provision for bonuses and ¥13.609 million in asset retirement obligations, offset by a ¥96.249 million decrease resulting from payments of accounts payable and income taxes payable, among other items.」

「The main factors were the recognition, from the current fiscal year, of ¥25 million in long-term deposits received representing grants awarded following selection for AMED's Drug Discovery Support Promotion Program / Pre-designation Practical Application Support Program for Orphan Drugs, and ¥4.566 million in provision for bonuses, offset by a ¥95.957 million decrease resulting from payments of accounts payable and income taxes payable, among other items.」

「The main factors were a ¥12.5 million increase in long-term deposits received, representing grants from AMED, offset by a ¥36.156 million decrease resulting from payments of accounts payable and income taxes payable, among other items.」

「To this end, we will advance research and development while securing new partners, obtaining research and development grants and, as necessary, raising funds from investors.」